Drug Trial Radar · NCT04513717
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,753
Actual
Start
Jan 21, 2021
Primary completion
Dec 31, 2033
Study completion Dec 31, 2038
Sponsor
- Lead sponsor
- NRG OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Aug 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Conditions
- Prostate Adenocarcinoma
- Stage III Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
Interventions
ApalutamideDrug
Given PO
BicalutamideDrug
Given bicalutamide
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone ScanProcedure
Undergo bone scan
BuserelinDrug
Given buserelin
Computed TomographyProcedure
Undergo CT scan
DegarelixDrug
Given degarelix
FlutamideDrug
Given flutamide
GoserelinDrug
Given goserelin
HistrelinDrug
Given histrelin
LeuprolideDrug
Given leuprolide
Magnetic Resonance ElastographyProcedure
Undergo MRI
Positron Emission TomographyProcedure
Undergo PET scan
Quality-of-Life AssessmentOther
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
Radiation TherapyRadiation
Undergo radiation therapy
RelugolixDrug
Given relugolix
TriptorelinDrug
Given triptorelin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Metastasis-free survival (MFS)Time frame: From randomization to the date of detection of distant metastasis on standard imaging or date of death from any cause, assessed up to 13 years
- Sexual quality of life (De-intensification study)Time frame: Up to 13 years
- Hormonal quality of life (De-intensification study)Time frame: Up to 13 years
- Fatigue (Intensification study)Time frame: Up to 13 years
Locations
602 sites in 2 countries. Site status is shown where the registry gives one.
Fairbanks Memorial Hospital
Fairbanks, Alaska
Banner MD Anderson Cancer Center
Gilbert, Arizona
Arizona Center for Cancer Care - Gilbert
Gilbert, Arizona
Arizona Center for Cancer Care-Peoria
Peoria, Arizona
Arizona Center for Cancer Care - Phoenix
Phoenix, Arizona
Arizona Center for Cancer Care - Scottsdale
Scottsdale, Arizona
University of Arizona Cancer Center-North Campus
Tucson, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California
Enloe Medical Center
Chico, California
City of Hope Corona
Corona, California
City of Hope Comprehensive Cancer Center
Duarte, California
Kaiser Permanente Dublin
Dublin, California
UC San Diego Health System - Encinitas
Encinitas, California
Kaiser Permanente-Fremont
Fremont, California
Palo Alto Medical Foundation-Fremont
Fremont, California
Washington Hospital
Fremont, California
Kaiser Permanente-Fresno
Fresno, California
Marin General Hospital
Greenbrae, California
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California
City of Hope at Irvine Lennar
Irvine, California
UC San Diego Moores Cancer Center
La Jolla, California
City of Hope Antelope Valley
Lancaster, California
Los Angeles General Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Fremont - Rideout Cancer Center
Marysville, California
Memorial Medical Center
Modesto, California
Kaiser Permanente-Modesto
Modesto, California
Providence Queen of The Valley
Napa, California
Kaiser Permanente-Oakland
Oakland, California
Saint Joseph Hospital - Orange
Orange, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Palo Alto Medical Foundation Health Care
Palo Alto, California
Stanford Cancer Institute Palo Alto
Palo Alto, California
Kaiser Permanente-Roseville
Roseville, California
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California
Showing 40 of 602 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.